Nordic Nanovector: Results From Preclinical Studies of Betalutin® in Combination with Rituximab to Be Presented at ASH
Nordic Nanovector Announces Changes to the Board of Directors and Notice of Extraordinary General Meeting
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor